Literature DB >> 21205933

Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis.

Masashi Nakatani1, Masahiro Kokubo, Yutaka Ohsawa, Yoshihide Sunada, Kunihiro Tsuchida.   

Abstract

Myostatin, a member of the transforming growth factor (TGF)-β superfamily, plays a potent inhibitory role in regulating skeletal muscle mass. Inhibition of myostatin by gene disruption, transgenic (Tg) expression of myostatin propeptide, or injection of propeptide or myostatin antibodies causes a widespread increase in skeletal muscle mass. Several peptides, in addition to myostatin propeptide and myostatin antibodies, can bind directly to and neutralize the activity of myostatin. These include follistatin and follistatin-related gene. Overexpression of follistatin or follistatin-related gene in mice increased the muscle mass as in myostatin knockout mice. Follistatin binds to myostatin but also binds to and inhibits other members of the TGF-β superfamily, notably activins. Therefore, follistatin regulates both myostatin and activins in vivo. We previously reported the development and characterization of several follistatin-derived peptides, including FS I-I (Nakatani M, Takehara Y, Sugino H, Matsumoto M, Hashimoto O, Hasegawa Y, Murakami T, Uezumi A, Takeda S, Noji S, Sunada Y, Tsuchida K. FASEB J 22: 477-487, 2008). FS I-I retained myostatin-inhibitory activity without affecting the bioactivity of activins. Here, we found that inhibition of myostatin increases skeletal muscle mass and decreases fat accumulation in FS I-I Tg mice. FS I-I Tg mice also showed decreased fat accumulation even on a control diet. Interestingly, the adipocytes in FS I-I Tg mice were much smaller than those of wild-type mice. Furthermore, FS I-I Tg mice were resistant to high-fat diet-induced obesity and hepatic steatosis and had lower hepatic fatty acid levels and altered fatty acid composition compared with control mice. FS I-I Tg mice have improved glucose tolerance when placed on a high-fat diet. These data indicate that inhibiting myostatin with a follistatin-derived peptide provides a novel therapeutic option to decrease adipocyte size, prevent obesity and hepatic steatosis, and improve glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21205933     DOI: 10.1152/ajpendo.00430.2010

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  14 in total

1.  Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Henry T Keutmann; Thomas B Thompson
Journal:  Mol Endocrinol       Date:  2012-05-16

2.  Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Chandramohan Kattamuri; Kristof Nolan; Huaying Zhao; Yisrael Sidis; Henry T Keutmann; Thomas B Thompson
Journal:  J Biol Chem       Date:  2011-11-03       Impact factor: 5.157

Review 3.  Phenotypes of Obesity: How it Impacts Management.

Authors:  Meera Shah; Ryan T Hurt; Manpreet S Mundi
Journal:  Curr Gastroenterol Rep       Date:  2017-09-25

4.  Alteration in body composition in the portacaval anastamosis rat is mediated by increased expression of myostatin.

Authors:  Srinivasan Dasarathy; Sean Muc; Ashok Runkana; Kevin Daniel Mullen; Kristine Kaminsky-Russ; Arthur Joseph McCullough
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-07-28       Impact factor: 4.052

5.  Leptin treatment reduces body fat but does not affect lean body mass or the myostatin-follistatin-activin axis in lean hypoleptinemic women.

Authors:  Mary Brinkoetter; Faidon Magkos; Maria Vamvini; Christos S Mantzoros
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-04-19       Impact factor: 4.310

6.  Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans.

Authors:  Maria T Vamvini; Konstantinos N Aronis; Grigorios Panagiotou; Joo Young Huh; John P Chamberland; Mary T Brinkoetter; Michael Petrou; Costas A Christophi; Stefanos N Kales; David C Christiani; Christos S Mantzoros
Journal:  Eur J Endocrinol       Date:  2013-10-21       Impact factor: 6.664

Review 7.  Sarcopenic obesity: how do we treat it?

Authors:  Matthew F Bouchonville; Dennis T Villareal
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2013-10       Impact factor: 3.243

8.  Increasing muscle mass to improve metabolism.

Authors:  Alexandra C McPherron; Tingqing Guo; Nichole D Bond; Oksana Gavrilova
Journal:  Adipocyte       Date:  2013-04-01       Impact factor: 4.534

9.  Combined administration of testosterone plus an ornithine decarboxylase inhibitor as a selective prostate-sparing anabolic therapy.

Authors:  Ravi Jasuja; James C Costello; Rajan Singh; Vandana Gupta; Catherine S Spina; Gianluca Toraldo; Hyeran Jang; Hu Li; Carlo Serra; Wen Guo; Pratibha Chauhan; Navjot S Narula; Tyler Guarneri; Ayla Ergun; Thomas G Travison; James J Collins; Shalender Bhasin
Journal:  Aging Cell       Date:  2013-12-04       Impact factor: 9.304

10.  Production of bioactive chicken (Gallus gallus) follistatin-type proteins in E. coli.

Authors:  Sang Beum Lee; Sung Kwon Park; Yong Soo Kim
Journal:  AMB Express       Date:  2015-08-25       Impact factor: 3.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.